Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats
- PMID: 17443396
- DOI: 10.1007/s11095-007-9308-2
Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats
Abstract
Purpose: To demonstrate transdermal delivery of interferon alpha-2b (IFNalpha2b) in hairless rats through aqueous microchannels (micropores) created in the skin and enhanced by iontophoresis.
Materials and methods: The Altea Therapeutics PassPort System was configured to form an array of micropores (2.0 cm(2); 72 micropores/cm(2)) on the rat abdomen. The transdermal patch (Iomed TransQ1-GS-hydrogel) was saturated with an IFNalpha2b solution (600 microg/ml) and applied for 4 h. Delivery was evaluated with and without cathodic iontophoresis (0.1 mA/cm(2)). Intravenous delivery (0.4 microg/100 g body weight) was performed to support pharmacokinetic calculations.
Results: IFNalpha2b was not delivered through intact skin by itself (passive delivery) or during iontophoresis. However, passive delivery through micropores was achieved in vivo in rats. A dose of 397 +/- 67 ng was delivered over 6 h, with steady state serum concentrations reaching a plateau at 1 h post-patch application. These levels dropped rapidly after patch removal, and returned to baseline within 2 h of patch removal. Iontophoresis-enhanced delivery through micropores resulted in a two-fold increase in the dose delivered (722 +/- 169 ng) in the hairless rat.
Conclusions: In vivo delivery of IFNalpha2b was demonstrated through micropores created in the outer layer of the skin. Iontophoresis enhanced delivery through microporated skin in hairless rats.
Similar articles
-
Evaluation of acyclovir cream and gel formulations for transdermal iontophoretic delivery.Ther Deliv. 2012 Mar;3(3):327-38. doi: 10.4155/tde.11.152. Ther Deliv. 2012. PMID: 22833993
-
Enhanced transdermal delivery of tetracaine by electroporation.Int J Pharm. 2000 Jul 20;202(1-2):121-4. doi: 10.1016/s0378-5173(00)00432-4. Int J Pharm. 2000. PMID: 10915934
-
Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study.Drug Deliv. 2021 Dec;28(1):454-462. doi: 10.1080/10717544.2021.1889719. Drug Deliv. 2021. PMID: 33620010 Free PMC article.
-
Iontophoresis-based transdermal delivery systems.BioDrugs. 2002;16(5):339-47. doi: 10.2165/00063030-200216050-00003. BioDrugs. 2002. PMID: 12408738 Review.
-
Synergistic effect of enhancers for transdermal drug delivery.Pharm Res. 2000 Nov;17(11):1354-9. doi: 10.1023/a:1007522114438. Pharm Res. 2000. PMID: 11205727 Review.
Cited by
-
The effect of heat on skin permeability.Int J Pharm. 2008 Jul 9;359(1-2):94-103. doi: 10.1016/j.ijpharm.2008.03.032. Epub 2008 Mar 29. Int J Pharm. 2008. PMID: 18455889 Free PMC article.
-
Transdermal drug delivery.Nat Biotechnol. 2008 Nov;26(11):1261-8. doi: 10.1038/nbt.1504. Nat Biotechnol. 2008. PMID: 18997767 Free PMC article. Review.
-
Microsecond thermal ablation of skin for transdermal drug delivery.J Control Release. 2011 Aug 25;154(1):58-68. doi: 10.1016/j.jconrel.2011.05.003. Epub 2011 May 17. J Control Release. 2011. PMID: 21596072 Free PMC article.
-
Enhancement of skin permeability with thermal ablation techniques: concept to commercial products.Drug Deliv Transl Res. 2021 Jun;11(3):817-841. doi: 10.1007/s13346-020-00823-3. Drug Deliv Transl Res. 2021. PMID: 32696221 Free PMC article. Review.
-
Transport and delivery of interferon-α through epithelial tight junctions via pH-responsive poly(methacrylic acid-grafted-ethylene glycol) nanoparticles.J Drug Target. 2019 Jun-Jul;27(5-6):582-589. doi: 10.1080/1061186X.2018.1547732. Epub 2019 Mar 1. J Drug Target. 2019. PMID: 30457357 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources